Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "Global Metabolic Partnering 2015-2022: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering.

Global Metabolic Partnering 2015 to 2022 provides the full collection of 1100+ Metabolic disease deals signed between the world's pharmaceutical and biotechnology companies since 2015.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Metabolic disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Metabolic deals.

The report presents financial deal terms values for Metabolic deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Metabolic dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Metabolic dealmaking since 2015 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Metabolic deals since 2015. Deals are listed by headline value. The chapter includes the top 25 most active Metabolic dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Metabolic deals since 2015 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Metabolic partnering deals by specific Metabolic target announced since 2015. The chapter is organized by specific Metabolic therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Metabolic partnering deals signed and announced since 2015. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report includes deals for the following indications: Acromegaly, Addison's disease, Cirrhosis, Cushing's syndrome, Diabetes, Type 1, Type 2, Insipidus, Fatty liver, Gallstones, Goitre, Growth hormone disorders, Gynaecomastia, Inborn errors of metabolism, Phenylketonuria, Hyperaldosteronism, Hypercalcaemia, Hyperthyroidism, Hypocalcaemia, Hypogonadism, Hypopituitarism, Hypothyroidism, Liver disease, Nonalcoholic steatohepatitis (NASH), Lysosomal storage disorders, Nutrition and vitamins, Rickets, Pheochromocytoma, Primary bilary cirrhosis, Prolactinemia, Short stature, Syndrome of Inappropriate Antidiuretic Hormone (SIADH), Thyroid disease, plus other metabolic indications.

Report scope

Global Metabolic Partnering 2015 to 2022 includes:

In Global Metabolic Partnering 2015 to 2022, available deals and contracts are listed by:

Analyzing actual contract agreements allows assessment of the following:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Metabolic dealmaking

2.1. Introduction

2.2. Metabolic partnering over the years

2.3. Metabolic partnering by deal type

2.4. Metabolic partnering by industry sector

2.5. Metabolic partnering by stage of development

2.6. Metabolic partnering by technology type

2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for Metabolic partnering

3.1. Introduction

3.2. Disclosed financials terms for Metabolic partnering

3.3. Metabolic partnering headline values

3.4. Metabolic deal upfront payments

3.5. Metabolic deal milestone payments

3.6. Metabolic royalty rates

Chapter 4 - Leading Metabolic deals and dealmakers

4.1. Introduction

4.2. Most active in Metabolic partnering

4.3. List of most active dealmakers in Metabolic

4.4. Top Metabolic deals by value

Chapter 5 - Metabolic contract document directory

5.1. Introduction

5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

6.1. Introduction

6.2. Deals by Metabolic therapeutic target

Appendices

Appendix 1 - Directory of Metabolic deals by company A-Z since 2015

Appendix 2 - Directory of Metabolic deals by deal type since 2015

Appendix 3 - Directory of Metabolic deals by stage of development since 2015

Appendix 4 - Directory of Metabolic deals by technology type since 2015

For more information about this report visit https://www.researchandmarkets.com/r/7b8gbu

See more here:

Global Metabolic Partnering Report 2022: Deal Trends, Players and Financials Analysis of 1100+ Deals Signed Since 2015 - ResearchAndMarkets.com -...